David Strobl
Cardiovascular Disease · Lansing, MINPI 1861490658
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $379,800 of the $444,677 with a category attached, or 85.4%. 9 manufacturers reported payments, led by Amgen at 41.6% of the total. Reporting peaked in 2019 at $214,719 and has fallen 91.0% since, to $19,235 in 2025. Among cardiovascular disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 540 payments — averaging $823.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$185K
- Amarin Pharma, Inc.$161K
- Sanofi-aventis U.S. LLC$40K
- Esperion Therapeutics, Inc.$29K
- Kowa Pharmaceuticals America, Inc.$23K
- Regeneron Healthcare Solutions, Inc.$6K
- plus $52 from 3 others
Across 199 payments — averaging $2518.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$317K
- Kowa Research Institute, Inc.$108K
- Esperion Therapeutics, Inc.$72K
- Amarin Pharma, Inc.$4K
What the payments were for
- Consulting fees$35,6108%
- Speaking & faculty fees$379,80085%
- Travel & lodging$19,4724%
- Food & beverage$9,7452%
- Education$510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 236 | $185,056 |
| Amarin Pharma, Inc. | 206 | $161,413 |
| Sanofi-aventis U.S. LLC | 52 | $40,087 |
| Esperion Therapeutics, Inc. | 24 | $29,124 |
| Kowa Pharmaceuticals America, Inc. | 3 | $22,616 |
| Regeneron Healthcare Solutions, Inc. | 16 | $6,331 |
| Regeneron | 1 | $26 |
| AstraZeneca | 1 | $13 |
| GSK | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$444,677 in reported general payments places this provider in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 121 | $74,087 |
| Praluent PenAlirocumab | 25 | $14,521 |
| VascepaIcosapent Ethyl | 12 | $7,671 |
| Ezetimibe | 79 | $2,038 |
| Rosuvastatin Calcium | 81 | $1,329 |
| Atorvastatin Calcium | 14 | $340 |
| Amlodipine Besylate | 14 | $69 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Lansing
- Chad LinkLansing$315K
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- Steven AlmanyTroy$471K
- Herman KadoSouthfield$442K
- Douglas HorstmanshofRoyal Oak$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.